« Förderinformationen
Innovative Medicines Initiative 2 (IMI2)
Aktualität:
bis 02.12.2015
Fördergeber:
EU - Sonstige
Die Innovative Medicines Initiative 2 (IMI2) hat die Ausschreibungsentwürfe für den fünften IMI2 Call auf ihrer Homepage veröffentlicht. Es werden aktuell folgende Topics diskutiert:
- Patient perspective elicitation on benefits and risks of medicinal products from development through the entire life cycle, for integration into benefit risk assessments by regulators and health technology assessment bodies
- Diabetic kidney disease biomarkers (DKD-BM)
- Inflammation and Alzheimer's disease (AD): modulating microglia function - focussing on TREM2 and CD33
- Understanding the role of amyloid biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
- Evolving models of patient engagement and access for earlier identification of Alzheimer's disease: phased expansion study
- Apolipoprotein E (ApoE) biology to validated Alzheimer's disease targets
Weitere Informationen:
http://www.imi.europa.eu/content/future-topics
- Patient perspective elicitation on benefits and risks of medicinal products from development through the entire life cycle, for integration into benefit risk assessments by regulators and health technology assessment bodies
- Diabetic kidney disease biomarkers (DKD-BM)
- Inflammation and Alzheimer's disease (AD): modulating microglia function - focussing on TREM2 and CD33
- Understanding the role of amyloid biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
- Evolving models of patient engagement and access for earlier identification of Alzheimer's disease: phased expansion study
- Apolipoprotein E (ApoE) biology to validated Alzheimer's disease targets
Weitere Informationen:
http://www.imi.europa.eu/content/future-topics